↓ Skip to main content

Dove Medical Press

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Overview of attention for article published in Therapeutics and Clinical Risk Management, August 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

blogs
1 blog

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
15 Mendeley
Title
Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor
Published in
Therapeutics and Clinical Risk Management, August 2011
DOI 10.2147/tcrm.s23889
Pubmed ID
Authors

Ayad K Ali

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 7%
India 1 7%
Unknown 13 87%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 27%
Researcher 4 27%
Professor > Associate Professor 2 13%
Student > Master 2 13%
Lecturer > Senior Lecturer 1 7%
Other 2 13%
Readers by discipline Count As %
Medicine and Dentistry 6 40%
Pharmacology, Toxicology and Pharmaceutical Science 4 27%
Computer Science 2 13%
Agricultural and Biological Sciences 1 7%
Unknown 2 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2011.
All research outputs
#5,327,641
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#264
of 1,323 outputs
Outputs of similar age
#27,373
of 130,326 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 11 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 130,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.